DarioHealth Corp. expects the broader deployment of DarioIQ, its proprietary generative and agentic AI platform, to increase annual Business-to-Business-to-Consumer (B2B2C) recurring revenue by approximately 10% to 15% from existing customers. This projection excludes the impact of future customer wins or additional condition expansions. The company announced that DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth.

Performance Metrics and Data Utilization

DarioIQ increases active member engagement by 40% and improves member retention by 20% compared to control groups. These results are derived from development completed in the first half of 2026. The platform leverages a de-identified dataset of more than 13 billion proprietary real-world healthcare data points collected across Dario's business-to-consumer (B2C) experience. By combining biometric readings from U.S. Food and Drug Administration (FDA)-cleared connected devices, clinical history and member behavioral engagement patterns, DarioIQ determines the right message, delivered through the right channel, at the right time for each individual member.

Strategic Impact and ROI

The AI platform creates an additional opportunity to lift B2B2C annual recurring revenues from current clients alongside Dario's land-and-expand strategy. DarioIQ has the potential to further boost the company's proven return on investment (ROI) of 2.5X to 5X across its programs. "Higher engagement increases the lifetime value of members while improving customer ROI, enabling Dario to grow revenue without proportionally increasing customer acquisition costs," said Lara Dodo, Chief Operating Officer of Dario.

Executive Commentary

"AI is transforming healthcare, and we believe Dario is well-positioned to lead the industry in harnessing the power of one of the largest proprietary datasets to improve outcomes for patients and payers," said Erez Raphael, Chief Executive Officer of Dario. "In managing chronic health, Dario owns the whole stack. We own the devices, the data and the AI, built over more than a decade. DarioIQ turns that integrated stack into results we can measure for members and for the clients who pay for outcomes."

Future Expansion and Oversight

The company's recently announced expansion into provider-backed care is expected to increase the long-term value of DarioIQ by connecting AI-driven engagement directly to clinical intervention. As Dario expands into larger healthcare markets, the same AI engine can support a broader range of clinical workflows, provider interactions and reimbursement opportunities. DarioIQ operates with human and clinical oversight, privacy safeguards and continuous monitoring consistent with the company's responsible-AI practices.

DarioHealth Corp. has entered an agreement with a major health insurer in Arizona through its strategic channel partnership with Amwell, making its cardiometabolic solution available to hundreds of thousands of covered lives. The agreement targets the insurer's Administrative Services Only (ASO) book of business, enabling self-insured employers to adopt Dario's unified approach for diabetes, hypertension, and weight management. This expansion supports Dario's channel-led growth strategy by leveraging Amwell's infrastructure to lower customer acquisition costs and accelerate sales cycles.

The solution will be positioned as a differentiated offering within the insurer's ASO portfolio. Employers can deploy the solution at scale based on specific population needs, with Dario claiming a return on investment of up to 5x. The clinical efficacy is validated by more than 100 scientific studies, including a study funded by Sanofi, which demonstrated savings through fewer hospitalizations and improvements in systolic blood pressure, A1C, and hyperglycemic events.

Strategic Channel Expansion

This agreement demonstrates how Dario's channel strategy drives scalable access to large employer populations. By embedding Dario within the health plan ecosystem, the company aims to expand recurring revenue opportunities while delivering measurable clinical and economic outcomes. Dario currently has access to over 116 million covered lives through its expanding channel partnership network.

Multi-Condition Platform

Dario's platform delivers personalized interventions driven by data analytics and one-on-one coaching across multiple chronic conditions. The company serves 12 health plans, including three national carriers, and offers solutions for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The integration of monitoring, detection, and treatment within a single platform distinguishes Dario from pure engagement vendors by ensuring continuous care without member handoffs.

"This agreement demonstrates how our channel strategy is driving scalable, efficient access to large employer populations," said Erez Raphael, Chief Executive Officer of Dario. "By leveraging channel partner infrastructure and relationships, we can rapidly reach a high-value ASO population like this and embed Dario within the health plan ecosystem."